Growth Hormone Adding to Controlled Ovarian Hyperstimulation for Improving Embryo Quality

Infertility,Female Clinical Trial

Official title:
Growth Hormone Adding to Controlled Ovarian Hyperstimulation for Improving Embryo Quality：a Randomized Controlled Study

Status Recruiting

Clinical Trial Summary

GH plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.In this study, a prospective randomized control was used to explore the effect of GH adjuvant therapy on embryo quality.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03966339
Study type	Interventional
Source	Reproductive & Genetic Hospital of CITIC-Xiangya
Contact	Yi Tang, Doctor
Phone	0731-82355100
Email	cstangyi@sina.com
Status	Recruiting
Phase	N/A
Start date	August 1, 2019
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04411212` - G-CSF and PRP in Patients With Recurrent Implantation Failure	Phase 2
Recruiting	`NCT06174298` - The Role of Granulocyte Colony Stimulating Factor in Embryo Transfer Outcomes	Phase 4
Recruiting	`NCT05330130` - Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells	Phase 1
Recruiting	`NCT04178135` - Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subsequent COS Cycle of Older Patients With Unexpected Poor or Suboptimal Ovarian Response	N/A